NALIRIFOX

DRUG9 trials

Conditions

Advanced Lung CarcinomaBasal Cell NeoplasmCRC (Colorectal Cancer)Colorectal Cancer (CRC)KRAS G12AKRAS G12CKRAS G12DKRAS G12S

Phase 1

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

RecruitingNCT06483555

UNC Lineberger Comprehensive Cancer CenterBasal Cell Neoplasm, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma

Start: 2025-02-06End: 2027-08-01Target: 104Updated: 2026-04-01

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

RecruitingNCT06736717

University of Kansas Medical CenterPancreatic Cancer

Start: 2025-02-28End: 2027-01-31Target: 21Updated: 2025-02-06

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

RecruitingNCT06917079

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Advanced Lung Carcinoma, CRC (Colorectal Cancer), KRAS G12A +11

Start: 2025-03-31End: 2029-09-01Target: 387Updated: 2026-03-23

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

RecruitingNCT07030283

University of Colorado, DenverPancreatic Ductal Adenocarcinoma (PDAC)

Start: 2025-12-31End: 2030-07-01Target: 10Updated: 2026-02-02

Phase 2

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

RecruitingNCT05851924

Memorial Sloan Kettering Cancer CenterPancreatic Ductal Adenocarcinoma

Start: 2023-05-12End: 2026-05-31Target: 60Updated: 2025-06-05

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

RecruitingNCT06816914

Taichung Veterans General HospitalResectable Pancreatic Adenocarcinoma

Start: 2025-03-05End: 2028-02-05Target: 84Updated: 2025-02-20

NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial

RecruitingNCT07077551

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNENS

Start: 2025-04-22End: 2028-12-31Target: 28Updated: 2025-07-22

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

RecruitingNCT07163273

Northwell HealthPancreatic Ductal Adenocarcinoma

Start: 2025-06-20End: 2027-06-20Target: 41Updated: 2026-03-18

Phase 4

Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer

Active, not recruitingNCT07020468

Affiliated Cancer Hospital of Shantou University Medical CollegeColorectal Cancer (CRC)

Start: 2025-05-15End: 2027-05-31Target: 57Updated: 2025-06-13

Related Papers

Abstract 7104: BBO-11818: An orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models

Cancer Research2026-04-03

Data from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants

2026-04-01

Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants.

2026-03-06

Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia

Molecular Cancer Therapeutics2025-10-22

Abstract A063: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models